The Automated Breast Ultrasound Systems Market has witnessed significant growth and technological advancements in recent years. ABUS is a non-invasive imaging technique that aids in the early detection of breast cancer, particularly in women with dense breast tissue, where traditional mammography may be less effective. The increasing prevalence of breast cancer cases and growing awareness about the importance of early diagnosis have been the primary drivers of the market’s expansion.
ABUS offers several advantages over conventional methods, such as providing 3D images and reducing the dependency on operator expertise, leading to improved diagnostic accuracy and efficiency. Additionally, advancements in artificial intelligence and machine learning have further enhanced ABUS’s capabilities, enabling automated lesion detection and characterization.
The market has also been bolstered by the rising adoption of digital healthcare solutions and telemedicine, allowing for remote interpretation and consultation, thereby improving access to healthcare services for patients in remote areas. Moreover, increased investments in research and development have resulted in the launch of more sophisticated and user-friendly ABUS devices, encouraging their widespread adoption among healthcare providers.
Start Your Journey Towards Greatness And Prosperity By Grabbing Our Sample Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-606
The Automated Breast Ultrasound Systems Market is anticipated to reach US$ 7.23 billion by 2033, with a worth of US$ 1.95 billion in 2023. By 2033, the market is anticipated to have a CAGR of 14%. According to the most recent research report from ESOMAR-certified Future Market Insights (FMI), the Automated Breast Ultrasound Systems Market has been greatly fueled by the increasing prevalence of breast cancer around the world and the expansion of government programmes to promote breast cancer awareness. According to the study, over the next ten years, the market for automated breast ultrasound systems would expand at a CAGR of about 10%.
However, challenges persist, such as the high cost of ABUS equipment, which may limit its accessibility in certain regions. Moreover, despite the benefits, there remains a need for continued education and training of medical professionals to ensure optimal utilization of ABUS technology.
“Visibly rising consumer inclination towards radiation free imaging and diagnostics systems is likely to intensify sales of automated breast ultrasound system among diagnostics laboratories,” says the FMI analyst.
Key Takeaways from FMI’s Automated Breast Ultrasound Systems Market Study
- Increasing government investment to promote breast cancer awareness among women will bolster demand across the U.S.
- The U.K is expected to experience noteworthy growth as governments and private organizations aim at curbing high mortality rate due to breast cancer.
- Presence of modern healthcare infrastructure will increase automated breast ultrasound system adoption across Germany
- Saudi Arabia will offer lucrative opportunities owing to rapid urbanization and emergence of advance diagnostics centers.
- India is expected to exhibit increasing demand owing to increase in per capita income and to growing incidence of breast cancer among women.
- Hospitals are expected to lead the market driven by faster accessibility modern tool and availability of skilled professionals.
Competitive Landscape
GE Electric Co., Siemens A.G., Hitachi Ltd., SonoCiné Inc., Koninklijke are some prominent players operating in the automated breast ultrasound system market. They are focusing on improving the accuracy of automated breast ultrasound system for faster assessment of cancer screening in addition to getting government approval for their products.
For instance, Hitachi being the global leader in smart life & eco-friendly systems launched its latest automated breast ultrasound system “SOFIA” capable of scanning and acquiring image of the complete breast.
Koninklijke launched Philips EPIQ and Affiniti ultrasound systems as a part of its automated breast ultrasound system product range. Philips EPIQ is laced with an integrated eL18-4 transducer and employs anatomical intelligence for accurate imaging of the breast with high tissue density.
Enhance Your Understanding With Our Enlightening Methodology-Derived Insights! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-606
Key Segments Covered
By End User
- Hospitals
- Diagnostic Imaging Laboratories
- America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Western Europe
- EU-5
- BENELUX (Belgium, Netherlands, Luxembourg)
- NORDIC (Denmark, Finland, Iceland, Norway, Sweden)
- Rest of Europe
- Eastern Europe
- Poland
- Russia
- Rest of Eastern Europe
- Japan
- APEJ (Asia Pacific excluding Japan)
- China
- India
- ASEAN Countries
- Australia & New Zealand
- Rest of APEJ
- MEA
- GCC Countries
- South Africa
- Israel
- Turkey
- Iran
- Rest of Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
